BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension

Abstract Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebulized inhaled treprostinil, but it requires a time in...

Full description

Bibliographic Details
Main Authors: Leslie A. Spikes, Abubakr A. Bajwa, Charles D. Burger, Sapna V. Desai, Michael S. Eggert, Karim A. El‐Kersh, Micah R. Fisher, Shilpa Johri, Joanna M. Joly, Jinesh Mehta, Harold I. Palevsky, Gautam V. Ramani, Ricardo Restrepo‐Jaramillo, Sandeep Sahay, Trushil G. Shah, Chunqin Deng, Melissa Miceli, Peter Smith, Shelley M. Shapiro
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:Pulmonary Circulation
Subjects:
dry powder inhaler
PAH‐SYMPACT
pharmacokinetics
quality of life
treprostinil
Online Access:https://doi.org/10.1002/pul2.12063

Internet

https://doi.org/10.1002/pul2.12063

Similar Items